Successful renal replacement therapy of extreme ertugliflozin and alcohol induced euglycaemic ketoacidosis

Excerpt

Since its introduction in 2013, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have become a cornerstone in the treatment of type 2 diabetes. Moreover, numerous cardiovascular and renal outcomes trials and their meta-analyses performed in patients with and without diabetes consistently reveal that this class of drug reduces cardiovascular events, and prevents heart failure and renal disease. Thus, the broad scope of application of SGLT2 inhibitors is now widely accepted. However, since 2015 shortly after their approval an increasing number of cases of euglycaemic diabetic ketoacidosis (EDKA) related to SGLT2 inhibitors have been described [1]. Consequently, the FDA alert on Euglycemic ketaocidosis and SGLT2 inhibitors provided updated warnings concerning the critical use and precautions for the treatment with SGLT2 inhibitors [2]. …